Literature DB >> 17641521

Stereotactic body radiotherapy for unresectable pancreatic cancer.

Stephanie T Chang1, Karyn A Goodman, George P Yang, Albert C Koong.   

Abstract

Pancreatic cancer is a devastating disease with few effective treatment modalities. Recent technological advances have made possible the delivery of single-fraction stereotactic body radiotherapy (SBRT) to patients with locally advanced pancreatic tumors. This paper presents experience at Stanford University with SBRT for patients with unresectable pancreatic cancer. Pancreatic tumors of up to 100 cm3 could be treated. Patients achieved greater than 90% local control for the remainder of their lives. Currently, the standard dose for pancreatic tumors treated at this institution is 25 Gy given in a single fraction. Four-dimensional CT and PET scans have been essential for optimal treatment planning. PET-CT scanning may be a more effective method for evaluating tumor response than conventional CT scanning. Adjuvant systemic therapies could be administered in coordination with SBRT. SBRT is an effective method of treating patients resulting in excellent local control. Current research is aimed at defining the optimal method of combining this treatment with other cancer therapies.

Entities:  

Mesh:

Year:  2007        PMID: 17641521     DOI: 10.1159/000106048

Source DB:  PubMed          Journal:  Front Radiat Ther Oncol        ISSN: 0071-9676


  6 in total

Review 1.  Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.

Authors:  Xiao-Yi Wang; Feng Yang; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

2.  The current role of PET-CT in the characterization of hepatobiliary malignancies.

Authors:  Ginseppe Garcea; Seok Ling Ong; Guy J Maddern
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

3.  (125)I particle implantation combined with chemoradiotherapy to treat advanced pancreatic cancer.

Authors:  Y-P Yu; Q Yu; J-M Guo; H-T Jiang; X-Y Di; Y Zhu
Journal:  Br J Radiol       Date:  2014-04       Impact factor: 3.039

Review 4.  Pancreatic cancer and FOLFIRINOX: a new era and new questions.

Authors:  Robert De W Marsh; Mark S Talamonti; Matthew Harold Katz; Joseph M Herman
Journal:  Cancer Med       Date:  2015-02-19       Impact factor: 4.452

5.  Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas.

Authors:  Tiffany A Pompa; William F Morano; Chetan Jeurkar; Hui Li; Suganthi Soundararajan; Jaganmohan Poli; Wilbur B Bowne; Michael Styler
Journal:  Case Rep Oncol Med       Date:  2017-03-08

6.  On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations.

Authors:  Lorenzo Placidi; Angela Romano; Giuditta Chiloiro; Davide Cusumano; Luca Boldrini; Francesco Cellini; Gian Carlo Mattiucci; Vincenzo Valentini
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-07-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.